Eli Lilly and Company: Lupus Erythematosus, Systemic trials
The registry lists 11 Lupus Erythematosus, Systemic studies with Eli Lilly and Company as lead sponsor. 1 are open to participants now and 9 have results posted.
Phase 1 2Phase 2 2Phase 3 7(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- A Study of LY4298445 in Healthy Participants and Participants With Systemic Lupus Erythematosus (SLE) or Rheumatoid Arthritis (RA)RecruitingNCT07276958Phase 1
- A IMMA Master Protocol: A Study of LY3361237 in Participants With at Least Moderately Active Systemic Lupus ErythematosusTerminatedNCT05123586Phase 2Results posted
- A Study of Baricitinib in Participants With Systemic Lupus Erythematosus (SLE)TerminatedNCT03843125Phase 3Results posted
- A Study of Baricitinib in Participants With Systemic Lupus Erythematosus (SLE-BRAVE II)CompletedNCT03616964Phase 3Results posted
- A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus ErythematosusTerminatedNCT03616912Phase 3Results posted
- A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythematosus (SLE)CompletedNCT02708095Phase 2Results posted
- A Study of Tabalumab (LY2127399) Using Two Different Injection Methods in Participants With LupusTerminatedNCT02041091Phase 3Results posted
- On Open-Label Study in Participants With Systemic Lupus ErythematosusTerminatedNCT01488708Phase 3Results posted
- A Study of LY2127399 in Participants With Systemic Lupus ErythematosusCompletedNCT01205438Phase 3Results posted
- A Study of LY2127399 in Participants With Systemic Lupus ErythematosusCompletedNCT01196091Phase 3Results posted
- A Study of LY3361237 in Participants With Systemic Lupus ErythematosusCompletedNCT03933943Phase 1